Tags

Type your tag names separated by a space and hit enter

Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity.
Eur J Pharm Biopharm. 2013 Nov; 85(3 Pt A):550-9.EJ

Abstract

In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a mucoadhesive coating material in nasal vaccine delivery was investigated. The Hepatitis B surface Antigen (HBsAg) encapsulated PLGA, chitosan coated PLGA (C-PLGA), and Glycol chitosan coated PLGA (GC-PLGA) nanoparticles (NPs) were prepared. The formulations were characterized for particle size, shape, surface charge, and entrapment efficiency. The mucoadhesive ability of coated and non-coated NPs was determined using in vitro mucoadhesion and nasal clearance test. In addition, the systemic uptake and bio-distribution were also evaluated to understand the fate of NPs following nasal delivery. The immuno-adjuvant ability of various formulations was compared by measuring specific antibody titer in serum and secretory. The results indicated that PLGA NPs exhibit negative surface charge, whereas C-PLGA and GC-PLGA NPs exhibited positive surface charge. The GC-PLGA NPs demonstrated lower clearance and better local and systemic uptake compared to chitosan coated and uncoated PLGA NPs. In vivo immunogenicity studies indicated that GC-PLGA NPs could induce significantly higher systemic and mucosal immune response compared to PLGA and C-PLGA NPs. In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation.

Authors+Show Affiliations

Department of Pharmaceutical Sciences, Jawaharlal Nehru Technical University, Hyderabad, India; Research and Development, Shantha Biotechnics Limited (A Sanofi Company), Hyderabad, India.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article

Language

eng

PubMed ID

23831265

Citation

Pawar, Dilip, et al. "Development and Characterization of Surface Modified PLGA Nanoparticles for Nasal Vaccine Delivery: Effect of Mucoadhesive Coating On Antigen Uptake and Immune Adjuvant Activity." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, vol. 85, no. 3 Pt A, 2013, pp. 550-9.
Pawar D, Mangal S, Goswami R, et al. Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. Eur J Pharm Biopharm. 2013;85(3 Pt A):550-9.
Pawar, D., Mangal, S., Goswami, R., & Jaganathan, K. S. (2013). Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, 85(3 Pt A), 550-9. https://doi.org/10.1016/j.ejpb.2013.06.017
Pawar D, et al. Development and Characterization of Surface Modified PLGA Nanoparticles for Nasal Vaccine Delivery: Effect of Mucoadhesive Coating On Antigen Uptake and Immune Adjuvant Activity. Eur J Pharm Biopharm. 2013;85(3 Pt A):550-9. PubMed PMID: 23831265.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Development and characterization of surface modified PLGA nanoparticles for nasal vaccine delivery: effect of mucoadhesive coating on antigen uptake and immune adjuvant activity. AU - Pawar,Dilip, AU - Mangal,Sharad, AU - Goswami,Roshan, AU - Jaganathan,K S, Y1 - 2013/07/04/ PY - 2012/11/29/received PY - 2013/04/21/revised PY - 2013/06/14/accepted PY - 2013/7/9/entrez PY - 2013/7/9/pubmed PY - 2014/9/27/medline KW - Drug Delivery KW - Glycol chitosan KW - Hepatitis B surface antigen KW - Mucosal immunization KW - PLGA nanoparticles KW - Single shot vaccine SP - 550 EP - 9 JF - European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V JO - Eur J Pharm Biopharm VL - 85 IS - 3 Pt A N2 - In this study, the efficacy of mucoadhesive polymers, i.e., chitosan and glycol chitosan as a mucoadhesive coating material in nasal vaccine delivery was investigated. The Hepatitis B surface Antigen (HBsAg) encapsulated PLGA, chitosan coated PLGA (C-PLGA), and Glycol chitosan coated PLGA (GC-PLGA) nanoparticles (NPs) were prepared. The formulations were characterized for particle size, shape, surface charge, and entrapment efficiency. The mucoadhesive ability of coated and non-coated NPs was determined using in vitro mucoadhesion and nasal clearance test. In addition, the systemic uptake and bio-distribution were also evaluated to understand the fate of NPs following nasal delivery. The immuno-adjuvant ability of various formulations was compared by measuring specific antibody titer in serum and secretory. The results indicated that PLGA NPs exhibit negative surface charge, whereas C-PLGA and GC-PLGA NPs exhibited positive surface charge. The GC-PLGA NPs demonstrated lower clearance and better local and systemic uptake compared to chitosan coated and uncoated PLGA NPs. In vivo immunogenicity studies indicated that GC-PLGA NPs could induce significantly higher systemic and mucosal immune response compared to PLGA and C-PLGA NPs. In conclusion, GC-PLGA NPs could be a promising carrier adjuvant for the nasal vaccine delivery for inducing a potent immune response at mucosal surface(s) and systemic circulation. SN - 1873-3441 UR - https://www.unboundmedicine.com/medline/citation/23831265/Development_and_characterization_of_surface_modified_PLGA_nanoparticles_for_nasal_vaccine_delivery:_effect_of_mucoadhesive_coating_on_antigen_uptake_and_immune_adjuvant_activity_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0939-6411(13)00236-1 DB - PRIME DP - Unbound Medicine ER -